ROME Therapeutics logo

ROME Therapeutics Funding & Investors

Boston, MA

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

rometx.com

Total Amount Raised: $199,000,000

ROME Therapeutics' Investors

ROME Therapeutics Funding Rounds

  • Series B

    $72,000,000

    Series B Investors

    Alexandria Venture Investments
    Sigmas Group
    Johnson Innovation
    ARCH Ventures
    Bristol-Myers Squibb Company
    Andreessen Horowitz
    Axon Ventures
    Mirae Asset Capital
    Sanofi
    S32
    Casdin Capital
    Mass General Brigham Ventures
    Luma Group
    GV
    RS Participaties
    Eurofarma Ventures
  • Series B

    $77,000,000

    Series B Investors

    S32
    Sanofi
    Alexandria Venture Investments
    GV
    Arch Venture Partners
    Casdin Capital
    Andreessen Horowitz
    Mass General Brigham Ventures
  • Series A

    $50,000,000

    Series A Investors

    GV
    Partners Innovation Fund
    Arch Venture Partners
Funding info provided by Diffbot.